Signaling pathways in adenoid cystic cancers: Implications for treatment

Cancer Biology and Therapy

Volumn 8, Issue 20, 2009, Pages 1947-1951

  Gupta, Anjali K ^a   Wilke, Werner W ^a   Taylor, Erin N ^a   Bodeker, Kellie L ^a   Hoffman, Henry T ^a   Milhem, Mohammed M ^a   Buatti, John M ^a   Robinson, Robert A ^a  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

Adenoid cystic; Akt; EGFR; MAPK; Nelfinavir; Signaling

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; NELFINAVIR; PROTEIN KINASE B;

ADENOID CYSTIC CARCINOMA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BLOTTING, WESTERN; CARCINOMA, ADENOID CYSTIC; CELL LINE, TUMOR; CELL SURVIVAL; HEAD AND NECK NEOPLASMS; HIV PROTEASE INHIBITORS; HUMANS; IMMUNOHISTOCHEMISTRY; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NELFINAVIR; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 73549106092     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.20.9596     Document Type: Article

References (20)

1. Spiro RH, Huvos AG, Strong EW. Adenoid cystic carcinoma of salivary origin. A clinicopathologic study of 242 cases. Am J Surg 1974; 128:512-20.
2. Conley J, Dingman DL. Adenoid cystic carcinoma in the head and neck (cylindroma). Arch Otolaryngol 1974; 100:81-90.
3. Chummun S, McLean NR, Kelly CG, Dawes PJDK, Fellows S, Meikle D, et al. Adenoid cystic carcinoma of the head and neck. Brit J Plast Surg 2001; 54:476-80.
4. Bradley PJ. Adenoid cystic carcinoma of the head and neck: a review. Curr Opin Otolaryngo 2004; 12:127-32.
5. Spiro RH, Huvos AG, Strong EW. Adenoid cystic carcinoma: Factors influencing survival. Am J Surg 1979; 138:579-83.
6. Khan AJ, DiGiovanna MP, Ross DA, Sasaki CT, Carter D, Son YH, et al. Adenoid cystic carcinoma: a retrospective clinical review. Int J Cancer 2001; 96:149-58.
7. van der Wal JE, Becking AG, Snow GB, van der Waal I. Distant metastases of adenoid cystic carcinoma of the salivary glands and the value of diagnostic examinations during follow-up. Head & Neck 2002; 24:779-83.
8. Dodd RL, Slevin NJ. Salivary gland adenoid cystic carcinoma: A review of chemotherapy and molecular therapies. Oral Oncol 2006; 42:759-69.
9. Gupta AK, Cerniglia GJ, Mick R, et al. HIV Protease Inhibitors Block Akt Signaling and Radiosensitize Tumor Cells Both In vitro and In vivo. Cancer Res 2005; 65:8256-65.
10. PDR guide to drug interactions, side effects and indications. Montvale NJ, Thomson PDR 2006.
11. Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, et al. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy and apoptosis in vitro and in vivo. Clin Cancer Res 2007; 13:5183-94.
12. Juan Carlos Alcedo JMF, Juan Ramón Arosemena, Aníbal Urrutia. Imatinib mesylate as treatment for adenoid cystic carcinoma of the salivary glands: Report of two successfully treated cases. Head & Neck 2004; 26:829-31.
13. Faivre S, Raymond E, Casiraghi O, Temam S, Berthaud P. Imatinib Mesylate Can Induce Objective Response in Progressing, Highly Expressing KIT Adenoid Cystic Carcinoma of the Salivary Glands. J Clin Oncol 2005; 23:6271-3.
14. Ching-Hung Lin R-FY, Yung-Ming Jeng, Chin-Yuan Tzen, Chiun Hsu, Ruey-Long Hong. Unexpected rapid progression of metastatic adenoid cystic carcinoma during treatment with imatinib mesylate. Head & Neck 2005; 27:1022-7.
15. Pfeffer MR, Talmi Y, Catane R, Symon Z, Yosepovitch A, Levitt M. A phase II study of Imatinib for advanced adenoid cystic carcinoma of head and neck salivary glands. Oral Oncol 2007; 43:33-6.
16. Glisson BS, Blumenschein G, Francisco M, Erasmus J, Zinner R, Kies M. Phase II trial of gefitinib in patients with incurable salivary gland cancer. J Clin Oncol 2005; 23:5532.
17. Haddad R, Colevas AD, Krane JF, Cooper D, Glisson B, Amrein PC, et al. Herceptin in patients with advanced or metastatic salivary gland carcinomas. A phase II study. Oral Oncol 2003; 39:724-7.
18. Glisson B, Colevas AD, Haddad R, Krane J, El-Naggar A, Kies M, et al. HER2 Expression in Salivary Gland Carcinomas: Dependence on Histological Subtype. Clin Cancer Res 2004; 10:944-6.
19. Agulnik M, Cohen EW, Cohen RB, Chen EX, Vokes EE, Hotte SJ, et al. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands. J Clin Oncol 2007; 25:3978-84.
20. accrf.org. http://www.accrf.org/pdf/accrf-cellupdate-mar09.pdf. 2008; Web Page.